FindTrial
Sign In

Comparative research on 99mTc-Rituximab and 99mTc-sulfur colloid in sentinel lymph node imaging of breast cancer

Preliminary clinical study of 99mTc-Rituximab in sentinel lymph node imaging of breast cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900024990
Enrollment
Unknown
Registered
2019-08-06
Start date
2016-10-01
Completion date
Unknown
Last updated
2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Gold Standard:99mTc-Rituximab
Index test:99mTc-sulfur colloid

Sponsors

Shanxi Academy of medical sciences Shanxi Dayi Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Early primary breast cancer; 2. Clinical, imaging and biopsy findings of axillary lymph nodes were negative; 3. patients who received neoadjuvant chemotherapy.

Exclusion criteria

Exclusion criteria: 1. Clinical N2 axillary lymph node; 2. inflammatory breast cancer.

Design outcomes

Primary

MeasureTime frame
number of SLNs;identication rate;Kappa;—

Countries

China

Contacts

Public ContactWanchun Zhang

Shanxi Dayi Hospital

zhang_wanchun@126.com+86 13935131789

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 20, 2026